GlassScriptPhysician profile
Anna Michelle Fenstermaker
NPI 1396360327
$7,501.73
in general payments reported to CMS, 2019-2025
42 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $762 · 2022: $1,100 · 2023: $1,610 · 2024: $2,090 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,639.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,098.21 | 2021-2025 | Biktarvy |
| Abbvie INC. | $1,068.40 | 2021-2025 | |
| Novo Nordisk INC | $762.87 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Viiv Healthcare Company | $723.47 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Pfizer INC. | $541.87 | 2021-2025 | |
| Lilly USA, LLC | $445.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $414.32 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $217.10 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $212.59 | 2021-2025 | Gardasil 9, Belsomra, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $193.32 | 2021-2025 | Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $160.82 | 2022 | |
| Exact Sciences Corporation | $150.18 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $136.67 | 2023-2025 | |
| Amgen INC. | $128.25 | 2021-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $122.64 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Fenstermaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.